key
featur
firstgener
quinolon
poor
serum
tissu
concentr
therefor
inadequ
treatment
system
infect
use
urinari
tract
infect
sexual
transmit
diseas
andlack
signific
activ
p
aeruginosa
gramposit
bacteria
anaerob
group
includ
origin
quinolon
nalidix
acid
cinoxin
share
either
bicycl
quinolon
nucleu
naphthyridon
deriv
nucleu
nitrogen
atom
posit
figur
agent
avail
oral
use
use
limit
uncompl
urinari
tract
infect
achiev
adequ
serum
tissu
concentr
lack
signific
activ
p
aeruginosa
gramposit
bacteria
anaerob
key
featur
secondgener
quinolon
late
member
achiev
adequ
serum
tissu
concentr
use
treat
system
infect
excel
gramneg
activ
includ
p
aeruginosa
andonli
modest
activ
methicillinresist
aureu
mrsa
weak
activ
pneumonia
signific
anaerob
activ
group
includ
norfloxacin
lomefloxacin
enoxacin
ofloxacin
ciprofloxacin
addit
fluorin
atom
posit
quinolon
nucleu
replac
sidechain
nalidix
acid
piperazin
group
figur
markedli
enhanc
microbiolog
activ
agent
allow
coverag
wide
rang
gramneg
bacteria
includ
p
aeruginosa
earli
member
group
norfloxacin
lomefloxacin
enoxacin
avail
oral
releg
treatment
urinari
tract
infect
achiev
adequ
serum
tissu
concentr
replac
group
norfloxacin
cyclopropyl
moieti
structur
chang
posit
quinolon
nucleu
led
synthesi
ofloxacin
ciprofloxacin
figur
later
compound
improv
pharmacokinet
properti
enabl
achiev
excel
serum
tissu
concentr
either
oral
intraven
use
allow
widespread
use
urinari
tract
well
system
infect
also
concentr
pulmonari
alveolar
macrophag
give
enhanc
activ
intracellular
pathogen
chlamydia
mycoplasma
legionella
spp
despit
advanc
secondgener
agent
lack
adequ
activ
import
gramposit
bacteria
mrsa
pneumonia
clinic
use
activ
anaerob
bacteria
key
featur
thirdgener
quinolon
improv
pharmacokinet
allow
daili
dose
administr
andenhanc
activ
pneumonia
group
includ
levofloxacin
sparfloxacin
grepafloxacin
gatifloxacin
gemifloxacin
levofloxacin
lisom
ofloxacin
agent
group
structur
chang
modif
piperazin
group
quinolon
nucleu
addit
methyl
group
alkyl
ring
structur
posit
addit
methoxi
group
posit
figur
structur
chang
improv
pharmacokinet
compound
allow
singl
daili
dose
administr
enhanc
activ
pneumonia
drug
also
enhanc
antimicrobi
activ
legionella
chlamydia
mycoplasma
spp
basi
minimum
inhibitori
concentr
mic
thirdgener
quinolon
levofloxacin
may
less
activ
secondgener
quinolon
ciprofloxacin
p
aeruginosa
howev
report
clinic
failur
levofloxacin
p
aeruginosa
infect
rare
may
vitro
disadvantag
levofloxacin
may
compens
pharmacokinet
profil
patient
result
superior
blood
tissu
concentr
grepafloxacin
remov
market
signific
potenti
lifethreaten
tachyarrythmia
caus
correct
qt
qtc
interv
prolong
sparfloxacin
remov
market
unaccept
phototox
gemifloxacin
recent
member
group
enhanc
activ
pneumonia
variabl
activ
anaerob
recent
gain
us
fda
approv
use
cap
aecb
key
featur
fourthgener
quinolon
enhanc
activ
anaerob
group
includ
trovafloxacin
clinafloxacin
moxifloxacin
garenoxacin
structur
modif
halogen
substitut
posit
quinolon
clinafloxacin
use
naphthyridon
nucleu
place
quinolon
nucleu
result
enhanc
antimicrobi
activ
anaerob
bacteroid
fragili
addit
coverag
aerob
gramposit
gramneg
organ
although
moxifloxacin
activ
vitro
anaerob
efficaci
treat
anaerob
infect
establish
use
infect
approv
us
fda
us
fda
advis
reserv
trovafloxacin
therapi
lifethreaten
infect
requir
inpati
treatment
risk
hepatotox
clinafloxacin
withdrawn
market
signific
phototox
garenoxin
novel
desfluoro
quinolon
broad
antimicrobi
spectrum
coverag
similar
trovafloxacin
remov
fluorin
atom
differenti
drug
fluoroquinolon
may
decreas
toxic
yet
releas
market
despit
initi
report
favour
safeti
profil
hypotens
encount
garenoxacin
compar
drug
phase
iii
clinic
trial
clinic
signific
advers
effect
yet
determin
reevalu
antibacteri
research
develop
prioriti
develop
compani
bristolmy
squibb
recent
announc
product
reacquir
initi
licens
compani
toyama
chemic
quinolon
kill
bacteria
bind
inhibit
activ
bacteri
topoisomeras
particularli
topoisomeras
ii
dna
gyras
topoisomeras
iv
enzym
essenti
bacteri
dna
synthesi
mainten
dna
gyras
encod
gyra
gyrb
gene
induc
neg
supercoil
dna
wherea
topoisomeras
iv
encod
parc
pare
gene
design
grla
grlb
aureu
involv
dna
decaten
dna
gyras
primari
target
quinolon
gramneg
bacteria
topoisomeras
iv
primari
target
gramposit
bacteria
although
except
occur
resist
quinolon
aris
spontan
mutat
occur
parc
grlab
gyrab
gene
due
acquisit
resist
gene
case
macrolid
ermam
mefe
gene
methicillin
sccmec
resist
thu
fluoroquinolon
resist
aris
de
novo
mani
differ
geograph
foci
rather
spread
singl
clone
appear
ciprofloxacin
resist
canada
instanc
thought
due
select
pressur
fluoroquinolon
use
upon
multipl
indigen
unrel
strain
throughout
countri
horizont
spread
resist
clone
may
still
occur
although
appear
uncommon
date
gramposit
organ
singlestep
mutat
parc
grlab
gene
caus
lowlevel
resist
ciprofloxacin
mutat
gyrab
gene
alon
usual
associ
chang
phenotyp
highlevel
resist
occur
mutat
parc
grlab
gyrab
gene
gyra
may
primari
target
fluoroquinolon
bacteria
data
vitro
assay
show
singlestep
mutat
occur
aureu
pneumonia
frequenc
often
rang
thu
singlestep
lowlevel
resist
variant
probabl
common
mani
pulmonari
infect
sinc
bacteri
number
often
exceed
coloni
form
unit
cfu
g
tissu
variant
erad
second
mutat
may
lead
highlevel
resist
resist
may
also
result
decreas
outer
membran
permeabl
efflux
pump
latter
energydepend
process
limit
intracellular
accumul
antibacteri
result
lowlevel
resist
may
may
occur
conjunct
mutat
topoisomeras
gene
efflux
affect
activ
norfloxacin
ciprofloxacin
levofloxacin
gatifloxacin
gemifloxacin
activ
moxifloxacin
trovafloxacin
affect
least
import
differ
may
exist
abil
specif
fluoroquinolon
select
resist
variant
among
gramposit
respiratori
pathogen
instanc
ciprofloxacin
select
resist
variant
pneumonia
vitro
readili
grepafloxacin
gemifloxacin
trovafloxacin
levofloxacin
moxifloxacin
gatifloxacin
garenoxacin
also
select
resist
variant
methicillinsensit
resist
aureu
frequent
levofloxacin
trovafloxacin
gatifloxacin
garenoxacin
overal
quinolon
gatifloxacin
moxifloxacin
desfluoro
quinolon
garenoxacin
appear
select
resist
mutant
pneumonia
aureu
lower
rate
older
quinolon
clear
differ
exist
may
function
intrins
activ
compound
bacteria
instanc
one
studi
show
activ
compound
pneumonia
gemifloxacin
mic
follow
clinafloxacin
mic
trovafloxacin
mic
grepafloxacin
moxifloxacin
mic
gatifloxacin
mic
levofloxacin
mic
ciprofloxacin
mic
intrins
activ
compound
combin
pharmacokinet
profil
may
key
understand
abil
thwart
foster
emerg
resist
see
discuss
pharmacodynam
section
insight
resist
seen
vitro
assay
predict
perform
fluoroquinolon
clinic
practic
instanc
failur
ciprofloxacin
cure
pneumococc
infect
well
document
tabl
sever
patient
develop
mening
therapi
clinic
trial
employ
ciprofloxacin
treatment
aecb
pneumonia
found
persist
sputum
treat
patient
treatment
failur
due
organ
us
fda
subsequ
modifi
packag
insert
suggest
ciprofloxacin
use
drug
first
choic
treatment
presum
confirm
pneumonia
due
pneumonia
failur
levofloxacin
also
report
tabl
ii
ciprofloxacin
sever
patient
develop
mening
therapi
lead
one
group
suggest
drug
use
along
levofloxacin
result
suscept
test
becom
avail
note
mani
patient
studi
fail
levofloxacin
therapi
previous
expos
fluoroquinolon
also
report
other
failur
fluoroquinolon
report
date
may
occur
increas
use
drug
one
area
particular
concern
crossresist
among
fluoroquinolon
use
one
agent
lead
class
resist
fluoroquinolon
johnson
note
isol
ciprofloxacin
mic
one
studi
also
resist
moxifloxacin
weiss
report
outbreak
fluoroquinoloneresist
pneumonia
hospit
ward
ciprofloxacin
often
use
empir
therapi
lower
respiratori
tract
infect
outbreak
involv
patient
organ
either
singl
parc
doubl
parc
gyra
mutat
lead
lowlevel
highlevel
resist
ciprofloxacin
respect
crossresist
levofloxacin
mic
moxifloxacin
gatifloxacin
mic
observ
anoth
studi
urban
cowork
report
two
patient
fail
levofloxacin
therapi
isol
patient
increas
mic
gatifloxacin
moxifloxacin
trovafloxacin
data
avail
prior
exposur
ciprofloxacin
report
mirror
crossresist
among
fluoroquinolon
seen
vitro
exposur
pneumonia
ciprofloxacin
rais
concern
misus
older
fluoroquinolon
may
select
lowlevel
resist
variant
becom
highli
resist
fluoroquinolon
second
mutat
although
resist
fluoroquinolon
report
vitro
isol
patient
preval
resist
among
pneumonia
respiratori
pathogen
larg
geograph
area
time
remain
low
tabl
iii
sahm
cowork
first
examin
fluoroquinolon
resist
rate
among
respiratori
pathogen
report
pneumonia
isol
collect
year
ciprofloxacin
use
us
resist
ciprofloxacin
howev
group
compar
isol
collect
respiratori
season
collect
found
statist
signific
increas
levofloxacin
resist
tabl
iii
other
also
examin
resist
newer
fluoroquinolon
among
pneumonia
instanc
brueggemann
et
al
examin
larg
group
isol
us
collect
found
resist
rate
levofloxacin
gatifloxacin
moxifloxacin
low
remain
stabl
doern
et
al
found
larg
number
isol
resist
levofloxacin
chang
year
observ
thornsberri
sahm
found
result
compar
isol
collect
respiratori
season
group
found
resist
levofloxacin
among
children
low
perhap
reflect
rel
lack
use
fluoroquinolon
popul
us
center
diseas
control
prevent
cdc
report
isol
recov
invas
pneumococc
diseas
found
ofloxacin
resist
increas
increas
levofloxacin
resist
interv
sahm
et
al
report
slightli
higher
rate
levofloxacin
resist
isol
collect
respiratori
season
analysi
isol
collect
communitybas
practic
us
instead
hospitalbas
laboratori
show
resist
either
levofloxacin
gatifloxacin
karchmer
report
result
protekt
us
prospect
resist
organ
track
epidemiolog
ketolid
telithromycin
unit
state
studi
isol
collect
respiratori
season
site
state
overal
levofloxacin
resist
rate
low
vari
geograph
southeast
northeast
howev
resist
rate
higher
area
countri
rate
highest
massachusett
colorado
alaska
citi
salem
massachusett
stamford
connecticut
dayton
ohio
denver
colorado
fluoroquinolon
resist
trend
also
examin
countri
longitudin
studi
canada
chen
et
al
report
preval
ciprofloxacinresist
pneumonia
strain
increas
seen
commonli
adult
children
reflect
use
fluoroquinolon
canada
resist
newer
fluoroquinolon
remain
low
zhanel
cowork
examin
almost
pneumonia
isol
collect
throughout
canada
found
resist
levofloxacin
howev
note
crossresist
among
fluoroquinolon
common
isol
resist
levofloxacin
increas
mic
ciprofloxacin
gatifloxacin
moxifloxacin
gemifloxacin
garenoxacin
powi
cowork
examin
isol
collect
part
canadian
bacteri
surveil
network
report
levofloxacin
resist
rate
increas
report
year
analysi
pneumonia
strain
collect
austria
show
levofloxacin
resist
rare
resist
moxifloxacin
gatifloxacin
uk
johnson
et
al
found
high
preval
moxifloxacin
resist
among
isol
refer
addit
test
resist
firstlin
agent
preval
resist
much
lower
among
isol
collect
routin
surveil
activ
glatz
cowork
hungari
also
found
higher
rate
fluoroquinolon
levofloxacin
resist
among
isol
resist
agent
case
penicillin
low
level
resist
newer
fluoroquinolon
report
sever
small
collect
isol
european
countri
rel
low
level
levofloxacin
resist
report
small
seri
taiwan
song
et
al
report
resist
rate
pneumonia
isol
collect
asian
countri
respiratori
season
report
resist
higher
levofloxacin
gatifloxacin
moxifloxacin
sever
larg
studi
attempt
monitor
preval
fluoroquinolon
resist
among
pneumonia
worldwid
instanc
sahm
cowork
report
larg
number
isol
collect
china
japan
sever
european
countri
winter
found
low
preval
resist
levofloxacin
among
pneumonia
hoban
et
al
report
data
sentri
antimicrobi
surveil
program
found
low
worldwid
preval
resist
levofloxacin
gatifloxacin
howev
data
north
america
examin
trend
resist
found
rate
resist
levofloxacin
among
pneumonia
increas
anoth
studi
resist
common
asiapacif
region
follow
north
america
europ
latin
america
worldwid
preval
resist
levofloxacin
moxifloxacin
protekt
surveil
studi
around
except
hong
kong
isol
resist
two
antibacteri
similar
high
resist
rate
hong
kong
also
report
ho
colleagu
summari
resist
pneumonia
readili
select
vitro
failur
among
patient
treat
ciprofloxacin
levofloxacin
well
document
howev
date
resist
rate
newer
fluoroquinolon
among
pneumonia
appear
low
although
sever
studi
suggest
rate
increas
localis
area
world
studi
shown
fluoroquinolon
resist
common
among
person
year
age
contrast
penicillin
resist
common
children
may
reflect
rel
use
antibacteri
age
group
may
chang
fluoroquinolon
approv
paediatr
use
crossresist
among
fluoroquinolon
seen
concern
thu
overus
older
agent
may
result
loss
efficaci
newer
agent
also
note
fluoroquinolon
resist
isol
often
resist
class
antibacteri
well
among
organ
resist
levofloxacin
report
cdc
also
resist
penicillin
resist
cefotaxim
resist
erythromycin
resist
cotrimoxazol
trimethoprimsulfamethoxazol
similar
trend
report
other
h
influenza
report
resist
ciprofloxacin
date
h
influenza
catarrhali
remain
sensit
newer
fluoroquinolon
efficaci
antibacteri
pathogen
often
express
term
mic
mic
defin
concentr
antibacteri
result
net
growth
inoculum
bacteria
incub
hour
laboratori
techniqu
determin
mic
well
interpret
breakpoint
use
label
organ
sensit
intermedi
resist
antibacteri
publish
current
use
clinic
laboratori
although
mic
use
success
manag
patient
past
statist
prove
limit
valu
predict
emerg
resist
fluoroquinolon
recent
investig
focus
effect
antibacteri
select
resist
variant
propos
environ
provid
small
differ
antibacteri
concentr
could
select
effect
bacteri
cultur
compris
subpopul
heterogen
resist
phenotyp
select
window
compart
bound
concentr
inhibit
suscept
bacteria
mic
concentr
inhibit
organ
lowlevel
resist
negri
cowork
examin
effect
antibacteri
exposur
mixtur
penicillinsuscept
resist
pneumonia
escherichia
coli
differ
mic
show
resist
strain
readili
select
antibacteri
concentr
within
select
compart
dong
colleagu
suggest
similar
principl
govern
select
resist
variant
aureu
expos
fluoroquinolon
defin
mutant
select
window
antimicrobi
concentr
rang
fall
mic
mutant
prevent
concentr
mpc
concentr
inhibit
growth
firststep
mutant
figur
report
experiment
data
theoret
analys
suggest
regimen
provid
fluoroquinolon
concentr
fall
within
select
window
select
resist
aureu
strain
wherea
regimen
provid
concentr
mpc
prevent
emerg
resist
strain
work
expand
theoret
analysi
effect
fluoroquinolon
pneumonia
date
exact
relationship
pharmacokinet
profil
bacteri
mic
mpc
delimit
select
window
defin
number
pharmacokinet
paramet
relationship
pharmacodynam
paramet
mic
mpc
propos
predict
effect
fluoroquinolon
bacteri
kill
emerg
resist
common
pharmacokinet
valu
examin
peak
concentr
antibacteri
dose
cmax
area
concentrationtim
curv
experiment
evid
shown
mani
case
quinolon
kill
rapidli
concentr
appreci
mic
target
microorgan
known
concentrationdepend
dosedepend
kill
contrast
timedepend
concentrationindepend
kill
often
seen
macrolid
effort
made
quantifi
relationship
pharmacokinet
paramet
cmax
pharmacodynam
paramet
mic
optimis
dose
administr
strategi
date
clinic
trial
examin
ratio
use
mpc
divisor
valu
pharmacodynam
ratio
cmaxmic
predict
outcom
fluoroquinolon
therapi
examin
studi
forrest
cowork
analys
result
ciprofloxacin
therapi
serious
ill
patient
varieti
infect
conclud
ratio
import
predictor
clinic
microbiolog
cure
applic
conclus
lowerrespiratori
tract
infect
uncertain
howev
infect
wound
urinari
tract
includ
analysi
patient
infect
pneumonia
major
patient
infect
aureu
p
aeruginosa
gramneg
aerob
conclus
studi
regard
efficaci
ciprofloxacin
may
also
confound
concomit
use
rifampin
azlocillin
patient
investig
later
examin
effect
three
differ
oral
grepafloxacin
dose
patient
aecb
patient
infect
wide
varieti
gramneg
gramposit
bacteria
vari
suscept
antibacteri
author
analys
aggreg
data
conclud
valu
inadequ
valu
suffici
bacteriolog
clinic
cure
howev
valu
associ
bacteriolog
clinic
cure
vari
organ
examin
instanc
grepafloxacinsensit
organ
catarrhali
haemophilu
spp
erad
regardless
valu
pneumonia
isol
erad
valu
respect
contrast
resist
organ
p
aeruginosa
erad
lowest
rang
erad
highest
rang
anoth
studi
perform
patient
receiv
ciprofloxacin
nosocomi
lowerrespiratori
tract
infect
conclud
cure
like
howev
applic
conclus
patient
pneumonia
catarrhali
infect
remain
uncertain
patient
studi
infect
organ
anoth
studi
analys
data
trial
levofloxacin
sometim
drug
administ
treatment
nosocomi
pneumonia
due
rang
gramposit
neg
bacteria
conclud
aucmic
ratio
optim
erad
pathogen
involv
one
trial
examin
abil
cmaxmic
ratio
predict
outcom
fluoroquinolon
therapi
basi
result
larg
multicentr
trial
involv
patient
varieti
pathogen
caus
respiratori
skin
urinari
tract
infect
treat
levofloxacin
preston
cowork
conclud
clinic
microbiolog
outcom
like
favour
cmaxmic
ratio
other
examin
pharmacodynam
ratio
specif
fluoroquinolon
pneumonia
laci
et
al
studi
effect
ciprofloxacin
levofloxacin
four
isol
vitro
infect
model
found
bacteri
growth
suppress
levofloxacin
ratio
rang
regrowth
occur
ciprofloxacin
highest
ratio
test
anoth
vitro
model
lister
sander
show
levofloxacin
erad
eight
strain
ratio
rang
ciprofloxacin
erad
five
strain
valu
craig
and
examin
effect
fluoroquinolon
pneumonia
murin
thigh
infect
model
found
kill
organ
surviv
studi
examin
effect
levofloxacin
gatifloxacin
patient
cap
aecb
caus
pneumonia
ambros
et
al
found
bacteri
erad
freedrug
ratio
overal
data
clinic
trial
limit
conclus
trial
confus
clinician
studi
suggest
gener
higher
cmaxmic
ratio
either
result
dose
administr
suscept
organ
lead
better
outcom
exact
valu
pharmacodynam
ratio
target
rapid
kill
prevent
resist
remain
elus
probabl
wide
varieti
organ
antibacteri
studi
limit
number
isol
test
use
differ
system
vitro
anim
clinic
trial
systemat
approach
use
limit
number
organ
tightli
control
condit
might
use
gain
insight
broad
pharmacodynam
principl
could
appli
tightli
control
clinic
trial
new
insight
evolut
resist
among
bacteria
expos
fluoroquinolon
use
novel
dose
administr
regimen
gain
seri
experi
vitro
pharmacodynam
system
experi
aureu
expos
simul
clinic
experiment
regimen
ciprofloxacin
respons
bacteria
monitor
time
exposur
clinic
regimen
twice
three
time
daili
initi
sensit
bacteria
becam
resist
evidenc
chang
mic
observ
whenev
bacteria
grown
high
number
inoculum
system
cfu
small
number
bacteria
lowlevel
resist
mic
rang
would
invari
present
appear
result
spontan
mutat
qrdr
grla
mani
case
mathemat
model
bacteri
kill
regrowth
system
function
dose
administr
done
model
use
predict
regimen
would
erad
cultur
regimen
consist
singl
high
dose
erad
lowlevel
resist
variant
present
inoculum
follow
standard
dose
administr
erad
sensit
major
regimen
test
vitro
system
cultur
erad
experi
suggest
key
bacteri
erad
target
lowlevel
resist
variant
present
inoculum
strategi
fit
well
concept
mpc
concentr
antibacteri
prevent
appear
firststep
mutant
shown
pharmacokinet
profil
keep
antibacteri
concentr
mpc
prevent
select
resist
variant
ultim
lead
bacteri
erad
vitro
system
howev
exact
relationship
pharmacokinet
profil
mpc
yet
elucid
simpli
keep
concentr
antibacteri
mpc
may
result
unaccept
toxic
mention
earlier
newer
fluoroquinolon
levofloxacin
gatifloxacin
gemifloxacin
moxifloxacin
garenoxacin
activ
ciprofloxacin
pathogen
pneumonia
aureu
appear
less
propens
select
resist
variant
use
clinic
dose
administr
regimen
vitro
system
may
newer
fluoroquinolon
better
pharmacokinet
profil
older
agent
higher
cmaxmpc
ratio
properti
intrins
compound
increas
activ
lower
mic
mpc
sever
newer
fluoroquinolon
moxifloxacin
may
allow
clinician
exceed
mpc
without
produc
toxic
pharmacokinet
paramet
commonli
encount
fluoroquinolon
market
present
tabl
iv
potenti
import
differ
among
agent
instanc
halflif
newer
fluoroquinolon
rang
hour
cmax
vari
steadi
state
vari
mg
hl
controversi
exist
valu
investig
believ
drug
protein
bound
biolog
activ
protein
bind
taken
account
cmax
valu
compound
gemifloxacin
garenoxacin
must
reduc
respect
contrast
investig
shown
protein
bind
littl
effect
fluoroquinolon
activ
fact
compound
concentr
alveolar
macrophag
rang
serum
cmax
ciprofloxacin
gatifloxacin
bronchial
epitheli
fluid
rang
serum
cmax
ciprofloxacin
moxifloxacin
may
import
clinic
howev
data
must
interpret
context
mic
mpc
pathogen
like
encount
lower
respiratori
tract
infect
ciprofloxacin
newer
fluoroquinolon
compar
basi
pharmacokinet
paramet
cmax
standard
dose
administr
regimen
mic
mpc
larg
collect
pneumonia
becom
evid
ratio
differ
consider
among
fluoroquinolon
tabl
v
instanc
valu
rang
valu
rang
ciprofloxacin
gemifloxacin
respect
similar
differ
appar
mpc
use
divisor
ratio
calcul
alveolar
macrophag
bronchial
epitheli
line
fluid
present
interpret
valu
applic
patient
care
yet
clarifi
gener
higher
pharmacodynam
ratio
serum
alveolar
macrophag
epitheli
line
fluid
probabl
lead
less
select
resist
better
patient
outcom
exact
valu
delimit
probabl
cure
failur
remain
defin
zhanel
et
al
review
four
studi
publish
prior
first
quarter
levofloxacin
dosag
day
compar
cefuroxim
axetil
cefaclor
treatment
aecb
bacteri
erad
rate
levofloxacin
rang
clinic
success
rate
rang
clinic
success
rate
cephalosporin
rang
four
studi
publish
sinc
review
compar
efficaci
levofloxacin
agent
tabl
vi
masterton
burley
compar
cours
oral
levofloxacin
patient
aecb
centr
ten
countri
found
equival
clinic
microbiolog
success
regimen
weiss
examin
rel
efficaci
levofloxacin
clarithromycin
cefuroxim
axetil
patient
aecb
efficaci
toler
three
agent
similar
case
file
et
al
report
result
studi
compar
levofloxacin
enhanc
amoxicillinclavulan
acid
formul
design
treatment
penicillinresist
pneumonia
regimen
success
erad
pneumonia
sputum
cure
patient
amsden
cowork
studi
patient
recruit
medic
centr
us
august
may
show
equival
azithromycin
levofloxacin
success
rate
endpoint
clinic
cure
improv
aecb
number
small
show
differ
rate
bacteri
erad
drug
equal
well
toler
fogarti
colleagu
summaris
result
four
studi
commiss
r
w
johnson
pharmaceut
research
institut
raritan
new
jersey
studi
efficaci
levofloxacin
cap
caus
erythromycinsensit
resist
pneumonia
tabl
vi
studi
independ
report
result
one
studi
comment
upon
previou
review
levofloxacin
efficaci
overal
microbiolog
clinic
success
good
respect
differ
among
patient
infect
erythromycinsensit
resist
organ
anoth
studi
report
fogarti
et
al
levofloxacin
compar
ceftriaxon
plu
erythromycin
given
intraven
follow
amoxicillinclavulan
acid
plu
clarithromycin
given
oral
overal
clinic
success
rate
bacteria
erad
rate
compar
gotfri
cowork
examin
rel
efficaci
oral
levofloxacin
extendedreleas
formul
clarithromycin
ambulatori
patient
cap
agent
appear
equal
efficaci
microbiolog
erad
rate
case
clinic
cure
improv
seen
patient
frank
cowork
compar
levofloxacin
combin
regimen
ceftriaxon
azithromycin
patient
hospitalis
moderatetosever
cap
regimen
given
least
day
although
ceftriaxon
administ
first
day
prevent
bacteraemia
due
pneumonia
regimen
equal
efficaci
bacteri
erad
clinic
cure
improv
rate
exceed
multicentr
postmarket
assess
levofloxacin
efficaci
treatment
cap
akpunonu
cowork
report
excel
success
varieti
respiratori
pathogen
one
clinic
trial
publish
examin
efficaci
one
new
respiratori
fluoroquinolon
nosocomi
pneumonia
trial
compar
high
dose
levofloxacin
given
intraven
oral
imipenemcilastatin
follow
oral
ciprofloxacin
antibacteri
could
ad
patient
infect
p
aeruginosa
mrsa
clinic
cure
microbiolog
erad
rate
similar
tabl
vi
zhanel
et
al
review
result
two
report
use
gemifloxacin
aecb
first
randomis
doubleblind
multin
studi
compar
efficaci
safeti
gemifloxacin
trovafloxacin
treatment
aecb
gemifloxacin
demonstr
similar
efficaci
trovafloxacin
clinic
bacteriolog
success
rate
gemifloxacin
versu
trovafloxacin
author
also
review
preliminari
result
globe
gemifloxacin
long
term
outcom
bronchiti
exacerb
studi
efficaci
safeti
cours
gemifloxacin
compar
standard
regimen
clarithromycin
patient
aecb
tabl
vii
clinic
bacteriolog
cure
rate
compar
group
howev
impact
treatment
longterm
week
clinic
outcom
assess
significantli
patient
receiv
gemifloxacin
clarithromycin
remain
free
aecb
recurr
vs
respect
sinc
review
zhanel
et
al
least
four
studi
publish
address
use
gemifloxacin
aecb
compar
convent
antibacteri
regimen
tabl
vii
file
cowork
compar
gemifloxacin
amoxicillinclavulan
acid
treatment
patient
aecb
randomis
doubleblind
multicentr
studi
two
drug
compar
clinic
cure
rate
although
microbiolog
efficaci
penicillin
regimen
somewhat
less
recent
wilson
cowork
compar
use
oral
gemifloxacin
given
daili
day
intraven
ceftriaxon
follow
oral
cefuroxim
axetil
given
maximum
day
treatment
hospitalis
patient
aecb
clinic
success
rate
followup
day
posttherapi
clinic
perprotocol
popul
significantli
higher
gemifloxacin
ceftriaxonecefuroxim
gemifloxacin
versu
ceftriaxonecefuroxim
treatment
differ
ci
correspond
clinic
result
intentiontotreat
popul
versu
respect
treatment
differ
ci
safeti
two
drug
regimen
also
compar
signific
differ
incid
type
advers
drug
effect
none
patient
studi
qtc
interv
chang
outsid
normal
rang
anoth
openlabel
noncompar
studi
ball
et
al
assess
clinic
bacteriolog
efficaci
gemifloxacin
aecb
found
drug
favour
clinic
bacteriolog
success
rate
sethi
et
al
studi
oral
gemifloxacin
oral
levofloxacin
adult
medic
centr
us
uk
germani
found
clinic
respons
drug
compar
zhanel
et
al
review
result
studi
file
et
al
compar
efficaci
gemifloxacin
trovafloxacin
treatment
cap
evalu
demonstr
similar
efficaci
clinic
microbiolog
three
studi
subsequ
publish
examin
use
gemifloxacin
cap
tabl
vii
lode
cowork
compar
use
oral
gemifloxacin
sequenti
therapi
intraven
ceftriaxon
oral
cefuroxim
without
macrolid
treatment
patient
hospitalis
cap
randomis
openlabel
multicentr
studi
clinic
bacteriolog
efficaci
oral
gemifloxacin
high
compar
regimen
without
macrolid
ball
cowork
found
gemifloxacin
achiev
clinic
microbiolog
success
subset
patient
cap
leophont
et
al
randomis
patient
cap
medic
centr
franc
poland
south
africa
either
gemifloxacin
oral
day
day
amoxicillinclavulan
acid
oral
day
clinic
cure
rate
group
almost
ident
zhanel
et
al
review
analysi
ramirez
cowork
result
two
randomis
doubleblind
studi
one
nonblind
studi
evalu
efficaci
gatifloxacin
treatment
aecb
pool
clinic
bacteriolog
cure
rate
seen
gatifloxacin
compar
either
levofloxacin
cefuroxim
axetil
vs
vs
clinic
bacteriolog
cure
respect
howev
superior
bacteriolog
erad
rate
pneumonia
h
influenza
seen
gatifloxacin
versu
compar
respect
three
studi
address
use
gatifloxacin
aecb
publish
recent
tabl
viii
one
group
compar
gatifloxacin
gatifloxacin
clarithromycin
cours
short
gatifloxacin
cours
result
clinic
cure
rate
compar
longer
gatifloxacin
clarithromycin
cours
microbiolog
erad
rate
report
treatment
group
anoth
group
assess
efficaci
toler
gatifloxacin
openlabel
noncompar
postmarket
trial
overal
clinic
cure
demonstr
patient
nicholson
et
al
found
clinic
cure
rate
patient
age
rang
year
old
three
randomis
doubleblind
trial
compar
efficaci
gatifloxacin
ceftriaxon
without
erythromycin
clarithromycin
levofloxacin
patient
cap
review
previous
trial
gatifloxacin
achiev
slightli
better
clinic
cure
bacteriolog
erad
rate
vs
compar
compar
vs
respect
least
seven
studi
address
use
gatifloxacin
cap
sinc
publish
tabl
viii
franca
carvalho
casilla
cowork
assess
effect
safeti
toler
gatifloxacin
patient
cap
two
openlabel
prospect
noncompar
multicentr
studi
demonstr
clinic
cure
rate
nicholson
et
al
evalu
gatifloxacin
elderli
patient
found
good
clinic
success
rate
pneumonia
infect
well
bacteri
erad
rate
less
effect
patient
year
old
anoth
studi
report
author
clinic
cure
rate
regardless
age
bacteriolog
erad
rate
document
presum
pneumonia
data
given
h
influenza
gotfri
et
al
report
result
teqc
communitybas
openlabel
prospect
noncompar
studi
oral
gatifloxacin
use
outpati
cap
drug
achiev
clinic
microbiolog
cure
rate
two
larg
trial
lode
et
al
demonstr
therapeut
equival
oral
gatifloxacin
either
clarithromycin
amoxicillinclavulan
acid
two
studi
recent
review
moxifloxacin
mgday
compar
clarithromycin
treatment
aecb
clinic
success
rate
moxifloxacin
rang
clinic
success
rate
clarithromycin
rang
five
studi
publish
sinc
review
compar
efficaci
moxifloxacin
agent
tabl
ix
deabat
et
al
report
result
larg
clinic
trial
involv
centr
us
moxifloxacin
compar
azithromycin
agent
produc
excel
erad
rate
key
respiratori
tract
pathogen
correspondingli
high
clinic
cure
success
rate
author
conclud
cours
moxifloxacin
equival
azithromycin
aecb
schaberg
et
al
report
find
larg
trial
involv
centr
countri
compar
moxifloxacin
one
tablet
daili
day
therapi
amoxicillinclavulan
acid
three
tablet
daili
day
overal
patient
well
either
regimen
miravitl
cowork
follow
spanish
patient
aceb
moxifloxacin
found
assess
patient
cure
week
therapi
advers
effect
low
italian
studi
grassi
cowork
found
oral
daili
moxifloxacin
equal
efficaci
daili
administr
intramuscular
ceftriaxon
therapeut
equival
moxifloxacin
amoxicillinclavulan
acid
demonstr
staraki
et
al
two
previous
review
studi
examin
efficaci
moxifloxacin
mgday
treatment
cap
clinic
success
rate
five
studi
publish
sinc
review
tabl
ix
hammerschlag
roblin
attempt
assess
rel
efficaci
moxifloxacin
clarithromycin
treatment
cap
caus
c
pneumonia
unlik
studi
defin
infect
basi
cultur
rather
serolog
unfortun
c
pneumonia
could
recov
nasopharyng
secret
enrol
patient
five
addit
patient
elimin
analysi
followup
cultur
done
treatment
small
number
patient
treat
clarithromycin
appear
efficaci
moxifloxacin
although
number
small
formal
statist
comparison
mani
patient
coinfect
pneumonia
h
influenza
bacteria
petitpretz
cowork
compar
efficaci
moxifloxacin
highdos
amoxicillin
mgday
patient
cap
larg
studi
involv
centr
countri
found
agent
gave
good
result
although
bacteri
erad
rate
clinic
cure
rate
slightli
higher
fluoroquinolon
frequenc
advers
effect
also
compar
group
anoth
larg
multin
multicentr
studi
carri
hoeffken
et
al
compar
efficaci
two
dose
moxifloxacin
mgday
clarithromycin
twice
day
regimen
well
toler
discontinu
rate
overal
clinic
cure
rate
approxim
three
regimen
higher
moxifloxacin
dosag
regimen
slightli
superior
erad
pathogen
either
regimen
finch
cowork
examin
rel
efficaci
moxifloxacin
penicillin
plu
macrolid
regimen
patient
cap
ill
enough
requir
parenter
therapi
intraven
moxifloxacin
switch
oral
therapi
soon
possibl
mandatori
period
given
addit
day
regimen
compar
highdos
amoxicillinclavulan
acid
initi
given
intraven
least
day
switch
oral
administr
clarithromycin
could
ad
discret
treat
physician
cover
atyp
pathogen
although
diagnos
serolog
patient
enrol
overal
moxifloxacin
therapi
superior
penicillin
plu
macrolid
regimen
term
rate
clinic
bacteriolog
cure
time
resolut
fever
vs
day
proport
patient
switch
oral
therapi
within
day
vs
length
hospit
stay
vs
day
larg
trial
involv
centr
throughout
world
torr
et
al
compar
oral
moxifloxacin
either
amoxicillin
clarithromycin
given
day
seventeen
percent
compar
group
receiv
amoxicillin
alon
receiv
clarithromycin
alon
receiv
drug
clinic
success
rate
test
regimen
approxim
moxifloxacin
better
toler
compar
regimen
therapeut
equival
moxifloxacin
combin
ceftriaxon
azithromycin
metronidazol
patient
initi
requir
intraven
therapi
cap
shown
katz
cowork
overal
newer
fluoroquinolon
often
achiev
clinic
cure
rate
patient
aecb
cap
rate
may
lower
hap
clinic
trial
gatifloxacin
gemifloxacin
moxifloxacin
nosocomi
pneumonia
publish
date
compar
clinic
trial
kind
report
garenoxacin
studi
review
littl
differ
clinic
success
rate
fluoroquinolon
compar
macrolid
test
gastrointestin
advers
effect
includ
alter
tast
anorexia
nausea
vomit
diarrhoea
effect
rang
incid
accord
quinolon
use
common
trovafloxacin
overal
rate
among
newer
fluoroquinolon
similar
although
nausea
vomit
diarrhoea
may
higher
moxifloxacin
gatifloxacin
compar
levofloxacin
cn
advers
effect
includ
dizzi
headach
somnol
less
commonli
agit
delirium
confus
psychosi
abnorm
vision
rare
seizur
seizur
may
encount
often
quinolon
use
treat
patient
histori
stroke
seizur
disord
patient
potenti
epileptogen
medic
nsaid
theophyllin
concomitantli
administ
cn
advers
effect
overal
incid
common
trovafloxacin
least
common
levofloxacin
gemifloxacin
dermatolog
advers
effect
includ
rash
pruritu
photosensit
hyperpigment
urticaria
phototox
link
primarili
presenc
halogen
atom
posit
quinolon
nucleu
compound
sparfloxacin
clinafloxacin
substitut
methyl
group
posit
gatifloxacin
moxifloxacin
significantli
reduc
phototox
potenti
dermatolog
advers
effect
rang
incid
seen
often
clinafloxacin
sparfloxacin
taken
market
least
often
trovafloxacin
gatifloxacin
moxifloxacin
recent
us
fdaapprov
fluoroquinolon
gemifloxacin
incid
rash
occur
commonli
among
women
year
age
musculoskelet
advers
effect
includ
arthropathi
chondrotox
tendon
tendon
ruptur
arthropathi
chondrotox
mainli
shown
immatur
laboratori
anim
seem
rare
human
perhap
limit
use
agent
among
children
howev
arthralgia
arthriti
report
occur
incid
children
juvenil
treat
ciprofloxacin
hand
case
report
tendon
ruptur
achil
tendon
use
ciprofloxacin
ofloxacin
norfloxacin
levofloxacin
risk
factor
tendinopathi
includ
renal
failur
corticosteroid
use
fluoroquinolon
caus
hypotens
tachycardia
prolong
qtc
interv
latter
effect
although
rare
encount
may
lead
cardiac
arrhythmia
patient
hypokalaemia
underli
heart
diseas
receiv
antiarrhythm
drug
prolong
qtc
interv
quinidin
procainamid
disopyramid
sotalol
amiodaron
recent
doubleblind
randomis
fourperiod
fourtreat
foursequ
crossov
trial
compar
effect
placebo
levofloxacin
moxifloxacin
ciprofloxacin
qtc
interv
prolong
drug
dose
twice
recommend
us
fda
routin
clinic
use
increas
qt
qtc
interv
compar
placebo
statist
signific
three
antibacteri
consist
greater
moxifloxacin
placebo
either
levofloxacin
ciprofloxacin
howev
advers
effect
experienc
volunt
studi
anoth
studi
demoli
cowork
compar
effect
moxifloxacin
versu
placebo
qtc
interv
healthi
men
women
doubleblind
randomis
placebocontrol
crossov
studi
ecg
record
rest
exercis
mean
sd
increas
rel
placebo
two
dose
across
wide
rang
rr
interv
although
chang
statist
signific
author
conclud
risk
moxifloxacininduc
torsad
de
point
would
low
moxifloxacin
howev
advis
caution
use
drug
patient
predispos
factor
torsad
de
point
electrolyt
disturb
bradycardia
coadministr
proarrhythm
drug
qtc
interv
prolong
also
report
sparfloxacin
grepafloxacin
remov
market
blood
pressur
chang
includ
hypertens
hypotens
postur
hypotens
report
incid
use
current
market
quinolon
histamin
releas
postul
one
respons
mechan
hypotens
sever
hypotens
may
occur
singl
dose
current
restrict
quinolon
trovafloxacin
mention
section
hypotens
occur
new
quinolon
garenoxacin
compar
phase
iii
trial
gatifloxacin
shown
mark
effect
glucos
toler
pancreat
function
howev
caus
brief
increas
serum
insulin
level
sever
persist
hypoglycaemia
caus
gatifloxacin
interact
oral
hypoglycaem
agent
report
least
three
case
report
ciprofloxacin
may
also
caus
slight
fluctuat
blood
sugar
level
patient
receiv
oral
hypoglycaem
drug
report
asymptomat
symptomat
hepat
pancreat
sever
hepatotox
death
associ
trovafloxacin
note
earlier
us
fda
advis
restrict
use
drug
patient
life
limbthreaten
infect
clinician
advis
monitor
serum
transaminas
indic
hepatobiliari
function
patient
receiv
hepat
metabolis
quinolon
trovafloxacin
moxifloxacin
summari
current
market
fluoroquinolon
appear
safe
well
toler
class
drug
although
sever
compound
either
withdrawn
market
temafloxacin
restrict
trovafloxacin
never
releas
sparfloxacin
grepafloxacin
perhap
garenoxacin
common
advers
effect
gastrointestin
overal
rate
low
discontinu
rate
among
newer
fluoroquinolon
perhap
advers
effect
concern
prolong
qtc
interv
sinc
lead
danger
arrhythmia
prolong
appear
greatest
moxifloxacin
unfortun
known
threshold
qt
interv
prolong
arrhythmia
occur
known
safe
known
postmarket
trial
ciprofloxacin
levofloxacin
arrhythmia
occur
rate
less
one
per
million
patient
whether
rate
higher
gatifloxacin
gemifloxacin
moxifloxacin
known
drug
use
extens
interest
qtc
interv
prolong
report
number
antimicrobi
includ
macrolid
imidazol
multival
cation
iron
zinc
calcium
aluminium
magnesium
may
form
insolubl
complex
oral
administ
fluoroquinolon
gastrointestin
tract
decreas
absorpt
antibacteri
exampl
drug
includ
multivitamin
miner
supplement
antacid
sucralf
drug
necessari
administ
least
hour
hour
oral
administr
fluoroquinolon
avoid
interact
antiretrovir
drug
didanosin
also
impair
absorpt
quinolon
drug
formul
contain
calcium
carbon
magnesium
hydroxid
buffer
probenecid
loop
diuret
cimetidin
increas
serum
fluoroquinolon
concentr
quinolon
inhibit
cytochrom
system
lead
increas
serum
concentr
drug
theophyllin
caffein
digoxin
ciclosporin
cyclosporin
warfarin
newer
fluoroquinolon
levofloxacin
gatifloxacin
moxifloxacin
less
effect
theophyllin
pharmacokinet
older
agent
fluoroquinolon
use
caution
patient
receiv
class
ia
procainamid
quinidin
disopyramid
class
iii
amiodaron
bretylium
sotalol
dofetilid
ibutilid
antiarrhythm
drug
well
erythromycin
cisaprid
antipsychot
tricycl
antidepress
prolong
qtc
interv
increas
potenti
fatal
tachyarrhythmia
concurr
use
corticosteroid
may
increas
risk
tendon
ruptur
especi
elderli
patient
fluoroquinolon
gatifloxacin
lesser
extent
ciprofloxacin
interact
oral
hypoglycaem
agent
may
result
seriou
hypoglycaemia
use
antibacteri
acut
bronchiti
discourag
aetiolog
often
viral
use
antibacteri
syndrom
result
unnecessari
cost
advers
drug
effect
potenti
select
resist
bacteria
clinic
evalu
radiograph
imag
microbiolog
studi
carri
patient
present
suggest
seriou
ill
pneumonia
sever
prolong
durat
ill
antibacteri
may
use
underli
bacteri
aetiolog
found
case
macrolid
tetracyclin
may
appropri
fluoroquinolon
reserv
secondlin
agent
patient
resist
bacteria
follow
local
trend
antibacteri
resist
may
valu
sever
guidelin
address
manag
aecb
publish
stratif
patient
allow
identif
patient
high
risk
infect
resist
bacteria
treatment
failur
complic
cours
highrisk
factor
includ
signific
impair
lung
function
four
episod
aecb
per
year
oral
corticosteroid
use
age
year
comorbid
condit
diabet
mellitu
heart
diseas
renal
failur
patient
aggress
approach
includ
sputum
gramstain
cultur
initi
empir
use
broadspectrum
antibacteri
justifi
avoid
treatment
failur
decid
whether
use
fluoroquinolon
altern
class
antibacteri
patient
aecb
help
inform
local
bacteri
resist
rate
unfortun
data
often
avail
larg
nation
intern
survey
may
differ
depend
upon
sourc
isol
hospit
vs
commun
instanc
one
larg
studi
hospit
isol
collect
us
respiratori
season
h
influenza
strain
resist
ampicillin
resist
cotrimoxazol
less
isol
resist
either
clarithromycin
azithromycin
full
pneumonia
isol
nonsuscept
intermedi
plu
resist
penicillin
vari
geograph
region
rang
south
atlant
new
england
studi
isol
collect
primari
care
provid
us
show
penicillin
nonsuscept
among
pneumonia
h
influenza
isol
resist
clarithromycin
anoth
studi
pneumonia
isol
collect
intermedi
resist
rate
penicillin
macrolid
cotrimoxazol
tetracyclin
copd
patient
aecb
highrisk
factor
usual
treat
outpati
basi
set
sputum
gramstain
cultur
seem
cost
effect
recommend
opinion
amoxicillinclavulan
acid
newer
macrolid
clarithromycin
azithromycin
use
firstlin
therapi
fluoroquinolon
reserv
secondlin
agent
data
show
recent
vitro
trend
macrolid
resist
among
pneumonia
clinic
failur
agent
concern
howev
controversi
relev
vitro
data
clinic
outcom
lack
superior
outcom
fluoroquinolon
compar
newer
macrolid
combin
clinic
studi
see
tabl
vi
ix
suggest
latter
agent
still
use
success
highrisk
patient
aecb
usual
treat
hospit
set
patient
sputum
gramstain
cultur
cost
effect
help
direct
antibacteri
therapi
patient
often
risk
infect
antibacterialresist
enter
gramneg
bacteria
p
aeruginosa
empir
therapi
may
start
intraven
third
fourthgener
cephalosporin
eg
ceftazidim
cefepim
aminoglycosid
p
aeruginosa
suspect
sputum
cultur
result
antibacteri
sensit
data
avail
one
author
suggest
fluoroquinolon
monotherapi
provid
good
clinic
outcom
higher
qualiti
life
lower
cost
set
idsa
recent
publish
guidelin
manag
cap
provid
recommend
choos
antimicrobi
therapi
recommend
includ
pathogenspecif
treatment
case
aetiolog
diagnosi
establish
empir
treatment
patient
aetiolog
diagnosi
known
whenev
aetiolog
organ
determin
chang
antimicrobi
agent
cost
effect
least
toxic
narrow
spectrum
encourag
recommend
treat
patient
requir
empir
antibacteri
select
base
like
pathogen
local
resist
pattern
comorbid
condit
sever
ill
site
care
recommend
decis
hospitalis
patient
base
assess
preexist
condit
may
compromis
safeti
patient
sent
home
port
pneumonia
outcom
research
team
sever
index
psi
score
greater
class
iii
clinic
judgment
although
concern
misus
overus
fluoroquinolon
could
lead
increas
pneumococc
resist
clinic
failur
use
fluoroquinolon
alon
recommend
sever
instanc
tabl
xi
american
thorac
societi
at
guidelin
manag
cap
also
includ
recommend
choos
antimicrobi
therapi
tabl
xi
idsa
guidelin
at
recommend
base
patient
stratif
accord
site
care
outpati
inpati
ward
intens
care
unit
icu
presenc
cardiopulmonari
diseas
presenc
modifi
factor
modifi
factor
defin
clinic
set
place
patient
risk
infect
drug
resist
pneumonia
enter
gramneg
bacteria
p
aeruginosa
risk
factor
infect
drugresist
pneumonia
includ
age
year
therapi
past
month
alcohol
immunosuppress
ill
includ
corticosteroid
therapi
hiv
infect
multipl
medic
comorbid
exposur
child
daycar
centr
risk
factor
infect
enter
gramneg
bacteria
includ
resid
nurs
home
underli
cardiopulmonari
diseas
multipl
medic
comorbid
recent
antibacteri
therapi
risk
factor
infect
p
aeruginosa
includ
structur
lung
diseas
bronchiectasi
antibacteri
therapi
day
past
month
corticosteroid
therapi
equival
mgday
prednison
malnutrit
recommend
antibacteri
regimen
given
tabl
xi
idsa
guidelin
fluoroquinolon
often
recommend
singl
agent
organis
made
recommend
treatment
cap
cdc
focus
primarili
drugresist
pneumonia
defin
mic
recommend
oral
plu
macrolid
tetracyclin
even
pneumococc
resist
concern
intraven
plu
macrolid
recommend
empir
therapi
hospitalis
patient
cap
cdc
emphasis
fluoroquinolon
use
routin
treat
cap
reserv
patient
fail
regimen
document
highlevel
drugresist
pneumonia
contrast
american
recommend
canadian
guidelin
call
respiratori
fluoroquinolon
first
choic
person
admit
hospit
at
guidelin
manag
hap
base
time
onset
hospitalis
diseas
sever
presenc
risk
factor
specif
organ
recommend
hap
begin
third
fourth
day
hospitalis
treat
cap
see
section
contrast
recommend
hap
encount
fifth
day
hospitalis
later
assum
result
organ
acquir
hospit
treat
accordingli
empir
earli
adequ
antibacteri
therapi
base
knowledg
like
infect
organ
shown
reduc
morbid
mortal
hap
at
defin
pathogen
like
aetiolog
hap
absenc
specif
risk
factor
see
bacteria
includ
e
coli
enterobact
spp
klebsiella
spp
proteu
spp
serratia
marcescen
h
influenza
methicillinsensit
aureu
pneumonia
risk
factor
addit
pathogen
includ
wit
aspir
recent
abdomin
surgeri
coma
head
trauma
recent
influenza
histori
intraven
drug
use
diabet
renal
failur
highdos
corticosteroid
prolong
icu
stay
structur
lung
diseas
antibacteri
use
onset
pneumonia
prolong
mechan
ventil
presenc
risk
factor
increas
probabl
infect
due
p
aeruginosa
acinetobact
spp
mrsa
anaerob
legionella
spp
initi
empir
therapi
hap
ventilatorassoci
pneumonia
patient
known
risk
factor
multidrugresist
pathogen
earli
onset
at
recommend
monotherapi
ceftriaxon
ampicillinsulbactam
ertapenem
quinolon
ciprofloxacin
levofloxacin
moxifloxacin
patient
late
onset
diseas
risk
factor
multidrugresist
bacteria
at
recommend
patient
treat
antipseudomon
cephalosporin
cefepim
ceftazidim
antipseudomon
carbapenem
imipenemcilastin
meropenem
inhibitor
combin
piperacillintazobactam
plu
antipseudomon
fluoroquinolon
ciprofloxacin
levofloxacin
aminoglycosid
linezolid
vancomycin
use
mrsa
suspect
studi
use
fluoroquinolon
hap
mainli
involv
use
ciprofloxacin
one
studi
show
equival
highdos
levofloxacin
imipenemcilastatin
follow
oral
ciprofloxacin
tabl
vi
use
newer
fluoroquinolon
gatifloxacin
moxifloxacin
evalu
set
ciprofloxacin
remain
activ
quinolon
p
aeruginosa
vitro
levofloxacin
may
effect
clinic
set
given
superior
pharmacokinet
despit
activ
p
aeruginosa
howev
use
fluoroquinolon
monotherapi
hap
justifi
sinc
high
clinic
failur
rate
evolut
resist
p
aeruginosa
observ
ciprofloxacin
monotherapi
fluoroquinolon
may
use
altern
aminoglycosid
combin
antipseudomon
concern
renal
dysfunct
drug
reliabl
synergist
p
aeruginosa
aminoglycosid
newer
fluoroquinolon
levofloxacin
moxifloxacin
gatifloxacin
gemifloxacin
sever
attribut
make
good
choic
therapi
lower
respiratori
tract
infect
excel
intrins
activ
pneumonia
h
influenza
catarrhali
atyp
respiratori
pathogen
pharmacokinet
allow
singl
daili
dose
administr
gener
well
toler
good
safeti
profil
clinic
trial
shown
achiev
high
microbiolog
erad
clinic
success
rate
compar
favour
newer
macrolid
unfortun
bacteria
becom
resist
agent
seri
simpl
spontan
mutat
numer
studi
rang
vitro
experi
case
report
larg
surveil
databas
shown
resist
occur
current
overal
preval
resist
newer
fluoroquinolon
low
necessarili
reassur
austin
et
al
point
typic
long
period
lowlevel
resist
preced
rapid
increas
resist
case
mrsa
vancomycinresist
enterococci
penicillinresist
pneumonia
recent
report
increas
preval
levofloxacin
resist
among
pneumococc
isol
collect
across
us
figur
exceed
certain
state
massachusett
colorado
worrisom
greater
concern
crossresist
among
fluoroquinolon
clearli
shown
occur
pathogen
expos
older
less
potent
agent
select
singlestep
lowlevel
resist
mutant
mutant
may
decreas
suscept
newer
fluoroquinolon
may
acquir
highlevel
resist
addit
mutat
second
target
gene
investig
suggest
less
potent
fluoroquinolon
ciprofloxacin
levofloxacin
abandon
favour
potent
one
gatifloxacin
moxifloxacin
gemifloxacin
treatment
cap
effort
prevent
class
resist
clinic
failur
document
ciprofloxacin
lead
us
fda
suggest
drug
use
lower
respiratori
tract
infect
caus
pneumonia
interest
similar
number
levofloxacin
failur
also
report
recommend
forthcom
theoret
ciprofloxacin
would
expect
less
efficaci
infect
caus
pneumonia
pharmacodynam
ratio
newer
agent
tabl
v
pharmacodynam
ratio
levofloxacin
gatifloxacin
moxifloxacin
gemifloxacin
whether
make
differ
patient
outcom
remain
seen
data
publish
recent
clinic
trial
involv
levofloxacin
gatifloxacin
moxifloxacin
gemifloxacin
suggest
littl
differ
among
fluoroquinolon
erad
rate
pneumonia
tabl
vi
ix
approach
origin
recommend
conserv
efficaci
pneumonia
also
seem
appropri
fluoroquinolon
approach
entail
reduct
prescrib
drug
whose
consumpt
correl
strongli
resist
ii
develop
new
formul
administr
strategi
deal
resist
strain
iii
use
antibacteri
maxim
capac
bacteri
erad
opinion
ciprofloxacin
use
lower
respiratori
tract
infect
concern
newli
releas
xr
formul
consist
bilay
matrix
first
layer
releas
ciprofloxacin
serum
tissu
within
hour
second
layer
releas
drug
slowli
allow
sustain
level
hour
peak
concentr
achiev
extendedreleas
formul
approxim
achiev
administr
convent
formul
xr
approv
us
fda
sole
oncedaili
treatment
urinari
tract
infect
concern
exposur
patient
low
sustain
concentr
ciprofloxacin
may
unintent
select
resist
pneumonia
colonis
respiratori
tract
extens
use
product
may
rapidli
acceler
class
resist
fluoroquinolon
situat
would
exacerb
clinician
opt
xr
treat
aecb
cap
conveni
opinion
key
erad
respiratori
pathogen
preserv
fluoroquinolon
class
focu
erad
lowlevel
resist
minor
subpopul
bacteria
often
exist
infect
end
optimis
cmaxmpc
ratio
import
opinion
agent
moxifloxacin
gemifloxacin
high
ratio
prefer
agent
ciprofloxacin
low
ratio
avoid
agent
levofloxacin
gatifloxacin
intermedi
ratio
may
worthwhil
consid
altern
dose
administr
strategi
could
involv
use
higher
dose
throughout
cours
therapi
approach
suggest
campion
et
al
singl
larg
dose
initi
administ
erad
lowlevel
resist
variant
follow
standard
administr
regimen
kill
sensit
major
opinion
would
valu
test
approach
vitro
experi
well
clinic
trial
